Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
DoEx-FDA leader joins new initiative designed to fight 'unfortunate reality' of vaccine landscape
DoMosaic Therapeutics adds to cancer combo pattern by licensing 2 clinical-stage drugs from Astex
DoBioxodes halts phase 2 stroke trial after successful interim review, plots registrational study
DoTariffs will make financial case for pharma M&A 'more difficult,' says Roche CEO
DoSanofi's oral TNF inhibitor misses mark in phase 2 psoriasis trial, prompting focus on combos
MiVanda sues FDA over hearing delay as agency points to mass layoffs, other litigation with the biopharma
MiTempus AI in line for $200M from AstraZeneca, Pathos deal to develop cancer model
MiGerman cancer antibody biotech eyes SPAC as route to Nasdaq
MiBoehringer inks Tessellate deal to slot synthetic lethal program into oncology pipeline
MiAscletis sees no benefit to high, fast oral GLP-1 dose titration, takes low, slow regimen forward
MiSanofi hands back cancer NK cell engager to Innate amid autoimmune pivot
Di'Severe consequences of government overreach': Harvard sues Trump admin over funding freeze
DiRoche looks to 'expand and upgrade' US research centers as part of $50B investment strategy in the country
MoAs Harvard battle escalates, HHS directs NIH not to tell universities about new grant freezes: reports
MoBrexit-related costs leave UK cancer patients, research in jeopardy: report
MoImmunovant narrows R&D focus as Roivant execs take CEO, CFO posts
MoTempest lays off 80% of workforce to ride out cash crunch
18.04.Alis offers exit option to biotechs tainted by tang of failure, providing way to return cash to shareholders
18.04.NIH nixes support for Pluri's radiation exposure cell therapy amid cost-cutting drive
18.04.Stealth biotech bags rights to VelaVigo bispecific in $440M deal
17.04.'An unwinnable situation': FDA delays force one biopharma to shelve phase 3 plans, WSJ reports
17.04.Elevation is latest biotech to face activist investor demands to wind down
17.04.Evotec axes 30% of assets as cost-cutting push hits pipeline
17.04.Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology
17.04.J&J calls time on Addex partnership 9 months after dropping failed epilepsy drug